1. Kinetics of p53 binding to promoter sites in vivo. Szak ST, Mays D, Pietenpol JA (2001) Mol Cell Biol 21(10): 3375-86
    › Primary publication · 11313463 (PubMed) · PMC100259 (PubMed Central)
  2. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Stewart ZA, Tang LJ, Pietenpol JA (2001) Oncogene 20(1): 113-24
    › Primary publication · 11244509 (PubMed)
  3. Development and implementation of a science training course for breast cancer activists: Project LEAD (leadership, education and advocacy development). Dickersin K, Braun L, Mead M, Millikan R, Wu AM, Pietenpol J, Troyan S, Anderson B, Visco F (2001) Health Expect 4(4): 213-20
    › Primary publication · 11703495 (PubMed) · PMC5060083 (PubMed Central)
  4. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Tahir SK, Han EK, Credo B, Jae HS, Pietenpol JA, Scatena CD, Wu-Wong JR, Frost D, Sham H, Rosenberg SH, Ng SC (2001) Cancer Res 61(14): 5480-5
    › Primary publication · 11454695 (PubMed)
  5. 4-hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c release. Ji C, Amarnath V, Pietenpol JA, Marnett LJ (2001) Chem Res Toxicol 14(8): 1090-6
    › Primary publication · 11511183 (PubMed)
  6. p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA (2000) Mol Cell Biol 20(12): 4210-23
    › Primary publication · 10825186 (PubMed) · PMC85790 (PubMed Central)
  7. p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Flatt PM, Polyak K, Tang LJ, Scatena CD, Westfall MD, Rubinstein LA, Yu J, Kinzler KW, Vogelstein B, Hill DE, Pietenpol JA (2000) Cancer Lett 156(1): 63-72
    › Primary publication · 10840161 (PubMed)
  8. Mechanisms of cell-cycle checkpoints: at the crossroads of carcinogenesis and drug discovery. Flatt PM, Pietenpol JA (2000) Drug Metab Rev 32(3-4): 283-305
    › Primary publication · 11139130 (PubMed)
  9. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL (1999) Clin Cancer Res 5(1): 35-42
    › Primary publication · 9918200 (PubMed)
  10. p21(Waf1/Cip1) inhibition of cyclin E/Cdk2 activity prevents endoreduplication after mitotic spindle disruption. Stewart ZA, Leach SD, Pietenpol JA (1999) Mol Cell Biol 19(1): 205-15
    › Primary publication · 9858545 (PubMed) · PMC83879 (PubMed Central)